Systems and Methods for Mental Health Assessment

The European Patent Office granted patent EP4232972A1 to Tibi Health, Inc. covering machine learning systems for mental health assessment. The patent, filed by inventors Ozem Irmak and Simal Irmak, includes claims across multiple health informatics classifications (G16H) and grants Tibi Health exclusive IP rights across 32 designated European states including Germany, France, the UK, Italy, and Spain.

IL-33 antagonist therapeutic agent, Mitsubishi Tanabe Pharma, endometriosis, EP3677281A1

IL-33 antagonist therapeutic agent, Mitsubishi Tanabe Pharma, endometriosis, EP3677281A1

Axl inhibitor therapeutic agent for solid cancers

The European Patent Office has granted Patent EP3695839A1 to ONO Pharmaceutical Co., Ltd. and Kyoto Prefectural Public University Corporation, covering an Axl inhibitor therapeutic agent for treating solid cancers. The patent protects novel compound compositions and their pharmaceutical applications. Designated states include all EU member states plus Switzerland, Norway, and other EPC contracting states.

Pyrrolo and imidazo pyridine compounds, protein kinase inhibitors, therapeutic applications

EPO published patent EP3697787A1 for HK inno.N Corporation covering pyrrolo[2,3-b]pyridine and imidazo[4,5-b]pyridine compounds as protein kinase inhibitors for therapeutic applications including cancer, metabolic, and neurological disorders.

Nucleic Acids Inhibiting Tmprss6 for Therapy

The European Patent Office published Patent EP3826720A2 granting Silence Therapeutics GmbH protection for nucleic acid compositions that inhibit Tmprss6 gene expression for therapeutic applications including iron chelation and neurological disorders. The patent covers A61K formulations and C12N15/113 classified nucleic acid sequences across 27 designated contracting states.

Method for Isolating Dopamine Neurons and Pharmaceutical Composition for Parkinson's Disease

The EPO granted Patent EP3591039A1 to S-BIOMEDICS covering a method for isolating dopamine neurons and a pharmaceutical composition containing those neurons for treating Parkinson's disease. The patent, with inventors KIM Dong-Wook, YOO Jeong-Eun, LEE Dongjin, PARK Sanghyun, KIM Jongwan, and CHO Myung Soo, designates 44 European states. The invention is classified under IPC categories for cell culture (C12N 5/0793), CNS-active pharmaceutical compositions (A61K 35/30), and anti-Parkinson agents (A61P 25/16).

Immunebridge Stem Cell Expansion Patent - Fluorene Derivatives

The European Patent Office published patent EP3700334A1 granted to Immunebridge Inc. covering compositions and methods for expanding hematopoietic stem cells using fluorene derivatives. The patent names inventors Jesse Cotari, Timothy Webb, and Zhan Wang, with broad IPC classifications spanning chemical compounds (C07C, C07D), pharmaceutical preparations (A61K), and therapeutic applications (A61P). The patent is designated across 32 European member states.

Probiotic Composition for Alcohol and Acetaldehyde Degradation

The European Patent Office published patent application EP3415155A1 for Cell Biotech Co., Ltd., covering a probiotic composition designed to degrade alcohol and acetaldehyde in the body. The patent identifies specific bacterial strains including Lactobacillus and Bifidobacterium species classified under multiple A61K compositions. The patent designates 33 European states including Germany, France, UK, Italy, and Spain.

Surrogate Binding Proteins Cancer Therapy Patent

The EPO published patent application EP3446707A1 for surrogate binding proteins targeting cancer therapy, filed by RevOpsis Therapeutics, Inc. and RevOpsis Holdings, LLC. The application covers immunotherapy compositions using engineered binding proteins classified under A61K 39/00, A61P 35/00 (cancer), and C07K 16/28, with all EU member states designated.

Anti-CD40 Antibodies and Methods of Use - Apexigen

The European Patent Office published patent EP3508500A1 granting Apexigen, Inc. exclusive rights to anti-CD40 antibody compositions and therapeutic methods. The patent covers C07K 16/28 antibodies targeting CD40 for treatment of oncology indications including A61P 35/00. Protection extends across 31 designated European Contracting States including Germany, France, UK, Italy, Spain, and the Netherlands.